Compare AbCellera Biologics Inc (ABCL) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $12.59. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | MSTZ | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $27.92 |
52-Week Low | $2.78 | $3.12 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MSTZ trades at $11.08, down 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10, resistance at $12. Financial ratios are unavailable, limiting fundamental assessment. Recent ETF-focused news mentions Strategy Inc. but provides no direct MSTZ updates, leaving a data gap for current company performance.
Outlook is cautious due to bearish technicals and lack of fundamental data. Investment opportunity hinges on forthcoming financial disclosures to clarify valuation and profitability. Primary risks include undefined business metrics and potential market volatility. Investors await earnings reports for clearer direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
